US Bancorp DE Has $109,000 Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

US Bancorp DE cut its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 40.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,358 shares of the company’s stock after selling 922 shares during the period. US Bancorp DE’s holdings in PROCEPT BioRobotics were worth $109,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRCT. Raleigh Capital Management Inc. acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at $32,000. IFP Advisors Inc acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at $58,000. Wilmington Savings Fund Society FSB acquired a new position in PROCEPT BioRobotics in the 3rd quarter valued at $64,000. Arcadia Investment Management Corp MI acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at $64,000. Finally, Canton Hathaway LLC acquired a new position in PROCEPT BioRobotics in the 3rd quarter valued at $66,000. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $57.62 on Monday. PROCEPT BioRobotics Co. has a 12-month low of $45.56 and a 12-month high of $103.81. The business has a 50-day simple moving average of $70.07 and a two-hundred day simple moving average of $79.05. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The stock has a market cap of $3.16 billion, a PE ratio of -29.55 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. Analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PRCT shares. Morgan Stanley dropped their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Truist Financial reissued a “buy” rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.29.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).